TC Pipelines, LP (TCP) Reaches $53.65 After 9.00% Up Move; 5 Analysts Bullish Axovant Sciences Ltd (AXON)

August 10, 2017 - By test

The stock of TC Pipelines, LP (NYSE:TCP) is a huge mover today! About 83,409 shares traded. TC Pipelines, LP (NYSE:TCP) has risen 7.30% since August 10, 2016 and is uptrending. It has underperformed by 9.40% the S&P500.The move comes after 8 months positive chart setup for the $3.72 billion company. It was reported on Aug, 10 by Barchart.com. We have $58.48 PT which if reached, will make NYSE:TCP worth $334.80M more.

Among 7 analysts covering Axovant Sciences (NYSE:AXON), 5 have Buy rating, 1 Sell and 1 Hold. Therefore 71% are positive. Axovant Sciences had 9 analyst reports since September 25, 2015 according to SRatingsIntel. The company was initiated on Tuesday, June 7 by Leerink Swann. Jefferies maintained the stock with “Buy” rating in Wednesday, April 19 report. Piper Jaffray initiated the stock with “Overweight” rating in Thursday, October 22 report. Oppenheimer initiated the stock with “Outperform” rating in Wednesday, December 7 report. The rating was maintained by Piper Jaffray on Thursday, April 13 with “Overweight”. The stock has “Buy” rating by H.C. Wainwright on Friday, January 8. Oppenheimer maintained Axovant Sciences Ltd (NYSE:AXON) rating on Wednesday, June 14. Oppenheimer has “Outperform” rating and $30 target. On Friday, September 25 the stock rating was maintained by Chardan Capital Markets with “Sell”. See Axovant Sciences Ltd (NYSE:AXON) latest ratings:

14/06/2017 Broker: Oppenheimer Rating: Outperform Old Target: $26.00 New Target: $30.00 Maintain
19/04/2017 Broker: IBC Rating: Neutral Old Target: $30.00 New Target: $33.00 Target Up
19/04/2017 Broker: Jefferies Rating: Buy New Target: $31.00 Maintain
13/04/2017 Broker: Piper Jaffray Rating: Overweight New Target: $32.00 Maintain

About 45,239 shares traded. Axovant Sciences Ltd (NYSE:AXON) has risen 97.46% since August 10, 2016 and is uptrending. It has outperformed by 80.76% the S&P500.

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The company has market cap of $2.42 billion. The Firm is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. It currently has negative earnings. The Firm intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Among 8 analysts covering TC Pipelines (NYSE:TCP), 2 have Buy rating, 1 Sell and 5 Hold. Therefore 25% are positive. TC Pipelines had 17 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was initiated by Ladenburg Thalmann on Friday, January 20 with “Neutral”. As per Monday, June 20, the company rating was downgraded by Barclays Capital. The firm earned “Sector Perform” rating on Monday, June 13 by RBC Capital Markets. The stock of TC Pipelines, LP (NYSE:TCP) has “Buy” rating given on Monday, December 21 by Bank of America. The stock of TC Pipelines, LP (NYSE:TCP) earned “Sector Perform” rating by RBC Capital Markets on Tuesday, August 11. The stock has “Neutral” rating by Goldman Sachs on Wednesday, July 20. The rating was maintained by Barclays Capital on Thursday, August 3 with “Underweight”. The stock of TC Pipelines, LP (NYSE:TCP) has “Neutral” rating given on Friday, May 27 by JP Morgan. Ladenburg Thalmann downgraded TC Pipelines, LP (NYSE:TCP) on Friday, May 6 to “Neutral” rating. As per Wednesday, July 27, the company rating was maintained by Citigroup.

TC PipeLines, LP is a master limited partnership. The company has market cap of $3.72 billion. The Firm acquires, owns and participates in the management of energy infrastructure businesses in North America. It has a 17.69 P/E ratio. The Company’s pipeline systems transport natural gas in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com